FDA warns about risks of compounded ketamine products for at-home use

The FDA issued a safety alert regarding compounded ketamine products — including oral formulations marketed through telemedicine platforms for at-home use — noting that compounded drugs are not FDA-approved, that sedation and dissociation can occur without monitoring, and that psychiatric and urinary adverse events have been reported.